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"Mechanism-Based Isocoumarin Inhibitors for Trypsin-Like Serine 
Proteases Involved in Blood Coagulation," C-M. Kam, J.C. Copher, and J.C. 
Powers (1987) J. Am. Chem. Soc. 109, submitted as a Communication to the 
Editor. 
Scientific Goals 
The goals of this research are the design, synthesis, and testing of 
synthetic inhibitors for the serine proteases involved in the blood 
coagulation pathway. Both novel transition state inhibitors and 
mechanism-based (suicide) inhibitors will be evaluated with the purpose of 
obtaining compounds which will selectively inhibit only one or a few of 
the activated coagulation factors, and compounds which will be general 
inhibitors of most of the activated coagulation factors. 
This research should lead to a better understanding of the active 
site structures of the blood coagulation serine proteases, both 
individually and in comparison to other trypsin-like serine proteases; may 
produce clinically useful drugs; should stimulate medicinal chemists in 
pharmaceutical companies to synthesize more enzyme targeted antithrombotic 
agents; and will provide new tools for the in vivo and in vitro study of 
the role of the individual coagulation factors in blood coagulation. 
Progress Report 
Mechanism-Based Inhibitors. We have made substantial progress in 
the synthesis of isocoumarin mechanism-based inhibitors for coagulation 




The structures of some of the inhibitors are 1, R = 
CH2CH2SC(=NH2 1- )NH2, X = H, Y = Cl; 2, R = CH2CH2CH2SC(=NH2 + )NH2, X = H, Y 
= Cl; 3, R = CH2CH2CH2NH3 + , X = H, Y = H; 4, R = CH2CH2CH2NH3 + , X = H, Y 
= Cl; 5, R = CH3, X = NHC(=NH2 + )1\TH2, Y = H; 6, R = CH3, X = 
NHC(=NH2 + )NH2, Y = Cl. 
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Incubation of the the isocoumarins with several coagulation enzymes 
and trypsin resulted in a time-dependent loss of enzymatic activity (Table 
I). The most potent inhibitor toward thrombin, trypsin and porcine 
pancreatic kallikrein was 4-chloro-7-guanidino-3-methoxyisocoumarin 6. 
Human protein D, human leukocyte elastase, human leukocyte cathepsin G, 
porcine pancreatic elastase, chymotrypsin and human plasma plasmin were 
inactivated with kob s /[I] values of 122, 6400, 11,000, 900, 7200, 3600 M - 
15-1. The guanidino isocoumarin 6 was quite selective and has its most 
potent inhibitory activity toward trypsin, thrombin and human plasma 
kallikrein with kob s /[I] values of 200,000 - 300,000 M- ls -1 . For all 
practical purposes, the high inhibition rates mean that stoichiometric 
amounts of inhibitor will inactivate the enzymes instantaneous. 4-Chloro-
3-(2-isothiureidoethoxy)isocoumarin 1 is the most potent inhibitor for 
plasma kallikrein, human factor XIa and human factor XIIa. 
The inhibition mechanism involves reaction of the 3-alkoxy-4- 
chloroisocoumarins 1, 2, 3, 4, and 5 with the active site serine residue 
of serine proteases to form acyl enzymes (top right) which deacylate 
slowly at varying rates or quickly upon the addition of hydroxylamine. If 
the 7-substituent on the isocoumarin ring is a guanidino (6) or amino 
group then further reaction through a quinone imine methide (center) can 
take place to give an irreversibly inactivated enzyme by reactions with an 
an active site nucleophile such as His-57 (bottom left). The quinone 
imine methide intermediate could also react with a solvent nucleophile to 
give an acyl enzyme (middle right) which can be reactivated by 
hydroxylamine. 
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Anticoagulant Activity. The 7-guanidino isocoumarin 6 is an 
effective anticoagulant in human plasma. The prothrombin time was 
prolonged from 12 sec (first appearance of clotting) to 2.8 min in the 
presence of 33 gm 6. The general serine protease inhibitor 3,4- 
dichloroisocoumarin prolonged the prothrombin time to 2 min at 330 11M. 
The isocoumarin 6 decomposed quite rapidly in human plasma (t1/2 = 5 min.) 
and preincubation of the inhibitor in plasma for 3 min resulted only in a 
80 % increase in prothrombin time. 
One specific aim for next year is the testing of the inhibitors with 
additional coagulation enzymes such as protein C and factor VIIa, and with 
other trypsin-like enzymes. Another goal is the synthesis of other 
isocoumarin derivatives with increased selectivity toward specific 
coagulation proteases. The PI has begun a program of modeling the 
inhibitors with the active sites of trypsin and porcine pancreatic 
kallikrein, the only two trypsin-like enzymes whose x-ray structures are 
known. 	We hope to learn how the inhibitors are interacting with the 
enzymes in order to introduce structural features which will lead both to 
increased selectivity and reactivity. Prof. Bud Suddath, an x-ray 
crystallographer at Georgia Tech is planning a crystal structure of one of 
our inhibitors bound to trypsin. This will yield important structural 
information on the mode of binding of the inhibitors. Finally, we plan to 
contact investigators who are carrying out animal studies of coagulation 
in order to have some of our inhibitors tested in animals. 
Transition State Analog Inhibitors. The first class of 
transition state inhibitors which we have been synthesizing are a-
ketoesters derived from Lys. These are prepared from the corresponding 
blocked amino acid or peptide. At present the following compounds have 
been prepared and purified. The synthesis and purification of these 
compounds turned out to be much more difficult than expected and it takes 







We expect that these compounds will interact with the active sites of 
trypsin-like serine proteases to form tetrahedral intermediates as shown 
below. Only preliminary kinetic studies have been carried out with with 
the a-ketoesters up to the present. We have shown that the first three 
derivatives inhibit trypsin with kinetic constants in the gm range. None 
have yet been tested with any of the coagulation factors or thrombin. In 
one preliminary experiment with the Bz- Lys-CO2Et, we found some inhibition 
of clotting in human plasma. 
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Our first priority for the next year, indeed the next few weeks, is 
to carry out kinetic studies with the a-ketoesters shown above. First we 
dm plan to obtain inhibition constants with the purified enzymes and then 
proceed to clotting assays with the most potent inhibitors. We plan to 
evaluate the results at that point and make a decision whether to proceed 
with the synthesis of longer peptidyl a-ketoesters derivatives or to move 
to inhibitors with other types of functional groups. 
Two other classes of inhibitors which we are planning to synthesize 
are boronic acids and trifluoromethyl ketones (shown below). Both of 
q these are transition state inhibitors and should react with the active 
site serine to form tetrahedral intermediates similar to that shown for 
the a-ketoesters. We have started with the boronic acids are now trying 
' to convert the m-amino boronic acid into the guanidino compound. The 
reaction appears to be working, but we have not yet been able to isolate 
and purify the product. Our goals for next year are to successfully 
synthesize and test this compounds and related derivatives. 
H2N B(OH)2 H2 N 	FIN 
N11 2 
B(OH)2 
    
H2 N coal 	132 	HN 	 COCF3 
NH2+ 
Highlights of Specific Scientific Accomplishments 
The guanidino and isothiureidoalkoxy isocoumarins 6 and 1 
developed in this study are the most potent inactivators yet reported 
for the several of the coagulation enzymes studied and 6 is one of 
the first mechanism-based (or suicide) serine protease inactivator 
which is active as an anticoagulant in human plasma. Thus we have 
taken the first step of the road toward the development of a 
significant class of new antithrombotic drugs. 














k obs /[IJ (M
-1 s -1 ) 
bovine 	bovine 	 porcine 	 human 	 human 	 human 	 bovine 
thrombin 	factor Xa 	pancreatic 	plasma 	 factor XIa 	factor XIIa 	trypsin 
kallikrein 	kallikrein 
1 4,700 5,600 12,000 280,000 b 44,000 39,000 32,000 
2 1,400 220 19,000 110,000 47,000 27,000 46,000 
3 2.7 NI c 4.7 29 28 3.2 1,200 
4 350 160 860 1,400 380 190 7,600 
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